| 1 |
35505742 | A Case of Abiraterone-Related Hypokalemia Leading to Torsades de Pointes and Cardiac Arrest. | 2022 Mar |
1 |
| 2 |
32397905 | Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature. | 2021 Jan |
1 |
| 3 |
33294761 | Congenital Adrenal Hyperplasia Causing Poor Response to Androgen Deprivation Therapy in Prostate Cancer. | 2021 Jan 1 |
1 |
| 4 |
33465380 | Abiraterone and D4, 3-keto Abiraterone binding to CYP17A1, a structural comparison study by molecular dynamic simulation. | 2021 Mar |
3 |
| 5 |
33742189 | Resistance to second-generation androgen receptor antagonists in prostate cancer. | 2021 Apr |
1 |
| 6 |
31727674 | Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation. | 2020 Feb |
6 |
| 7 |
31938799 | Pregnenolonyl-α-glucoside exhibits marked anti-cancer and CYP17A1 enzymatic inhibitory activities. | 2020 Feb 6 |
2 |
| 8 |
32045360 | Abiraterone acetate treatment lowers 11-oxygenated androgens. | 2020 Apr |
2 |
| 9 |
32274544 | [Combination therapy for metastatic hormone-sensitive prostate cancer: What? When? For whom?] | 2020 Jun |
1 |
| 10 |
32554434 | Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. | 2020 Sep |
12 |
| 11 |
32911627 | Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial. | 2020 Sep 8 |
1 |
| 12 |
32931809 | New 3β-hydroxysteroid-indolamine conjugates: Design, synthesis and inhibition of C6 glioma cell proliferation. | 2020 Dec |
1 |
| 13 |
32945940 | CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone. | 2020 Oct |
3 |
| 14 |
33854564 | Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037). | 2020 |
1 |
| 15 |
30209993 | Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target. | 2019 |
2 |
| 16 |
30413807 | Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer. | 2019 May |
1 |
| 17 |
30431391 | Comparative study of the binding mode between cytochrome P450 17A1 and prostate cancer drugs in the absence of haem iron. | 2019 Oct |
18 |
| 18 |
30537624 | An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5α-abiraterone, and their inactive glucuronide derivatives. | 2019 Jan 1 |
4 |
| 19 |
31017696 | A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. | 2019 Jun |
1 |
| 20 |
31390632 | Recognition and Treatment of Adrenal Insufficiency Secondary to Abiraterone: A Case Report and Literature Review. | 2019 |
1 |
| 21 |
31421381 | Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients. | 2019 Sep 15 |
1 |
| 22 |
31694496 | Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis. | 2019 Dec |
1 |
| 23 |
31933595 | CYP17A1 and Androgen-Receptor Expression in Prostate Carcinoma Tissues and Cancer Cell Lines. | 2019 Nov |
1 |
| 24 |
32743362 | Remarkable response to abiraterone acetate in castration-resistant prostate cancer patient with aggressive liver metastasis. | 2019 Jan |
1 |
| 25 |
28355968 | Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature. | 2018 Jun |
1 |
| 26 |
29027195 | TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. | 2018 Jul |
2 |
| 27 |
29710837 | Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency. | 2018 Apr 29 |
4 |
| 28 |
29792703 | Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2. | 2018 Jun 14 |
3 |
| 29 |
29807244 | Interaction of 17α-hydroxylase, 17(20)-lyase (CYP17A1) inhibitors - abiraterone and galeterone - with human sterol 14α-demethylase (CYP51A1). | 2018 Sep |
1 |
| 30 |
29939161 | HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. | 2018 Aug 1 |
1 |
| 31 |
29991699 | Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease. | 2018 Aug |
2 |
| 32 |
27683182 | A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. | 2017 Feb 15 |
1 |
| 33 |
28304025 | Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1. | 2017 Mar 28 |
3 |
| 34 |
28373265 | Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1. | 2017 Jun |
1 |
| 35 |
28463227 | Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. | 2017 Jun 1 |
2 |
| 36 |
28890368 | CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone. | 2017 Nov |
8 |
| 37 |
28893623 | CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2. | 2017 Nov |
3 |
| 38 |
28924064 | Circulating steroid hormone variations throughout different stages of prostate cancer. | 2017 Nov |
1 |
| 39 |
28977599 | Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone. | 2017 Oct 1 |
2 |
| 40 |
28978327 | Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial. | 2017 Oct 4 |
2 |
| 41 |
25907623 | Commentary on "Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel." Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A, Leibowitz-Amit R, Berger R, Keizman D, Department of Oncology, Rambam Medical Center, Haifa, Israel.: Prostate 2014 Apr;74(4):433-40; doi:10.1002/pros.22765. [Epub 2013 Dec 11]. | 2016 May |
1 |
| 42 |
26648519 | Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways. | 2016 Feb |
1 |
| 43 |
26714839 | Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. | 2016 Apr |
1 |
| 44 |
26954071 | CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone. | 2016 Jul 30 |
2 |
| 45 |
26965562 | Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. | 2016 Sep |
1 |
| 46 |
27083183 | The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer. | 2016 May |
2 |
| 47 |
27154414 | The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature. | 2016 Oct |
1 |
| 48 |
27344806 | [Abiraterone (CYP17 inhibitor)]. | 2016 May 20 |
1 |
| 49 |
27406023 | Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors. | 2016 Jul 12 |
2 |
| 50 |
27426448 | Cytochrome b5 Activates the 17,20-Lyase Activity of Human Cytochrome P450 17A1 by Increasing the Coupling of NADPH Consumption to Androgen Production. | 2016 Aug 9 |
1 |